Pliant Therapeutics Q4 2025 Earnings Report

Pliant Therapeutics EPS Results

• Actual EPS: -$0.35
• Consensus EPS: -$0.44
• Beat/Miss: Beat by +$0.09
• One Year Ago EPS: N/A

Pliant Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Pliant Therapeutics Announcement Details

• Quarter: Q4 2025
• Date: 3/11/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Pliant Therapeutics (NASDAQ:PLRX) (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrotic diseases. Headquartered in Redwood City, California, Pliant applies a precision medicine approach to target integrin-mediated signaling pathways implicated in the development and progression of fibrosis across organ systems.

The company’s lead product candidate, PLN-74809, is an oral small molecule designed to inhibit both αvβ1 and αvβ6 integrins in patients with idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). In preclinical studies, Pliant has also advanced research-stage integrin modulators aimed at addressing fibrosis in diabetic nephropathy and other indications with high unmet medical need.

Founded in 2015, Pliant has built its research and development capabilities around translational biomarkers and validated preclinical models. The company’s clinical programs are conducted through multi‐center studies in North America, with plans to expand patient enrollment into additional geographies as part of global development efforts.

Leadership at Pliant is led by President and Chief Executive Officer Vikram Shembekar, who brings extensive biopharmaceutical development experience. The management team combines expertise in clinical development, regulatory strategy and commercialization planning, positioning the company to advance its integrin-targeted pipeline toward potential regulatory approvals and eventual patient access.